Comparison of automated subcutaneous defibrillator screening between different pacing sites in cardiac pacing device carriers Authors: Manuel Molina-Lerma, Eva Cabrera-Borrego, Ricardo Rivera-Lopez, Pablo Sánchez-Millán, Jesús Peña Mellado, Antonio Arriaga Jiménez, Miguel Álvarez Published: 2023 ABSTRACT AbstractAimsThe compatibility of cardiac pacing with the presence of a subcutaneous implantable cardioverter-defibrillator (S-ICD) has been investigated, but S-ICD screening test results have not been compared among different pacing sites. The objective was to compare S-ICD screening results among different cardiac pacing sites and to assess the electrocardiographic predictors of success.Methods and resultsThis prospective single-centre study conducted automated S-ICD screening in 102 carriers of cardiac pacing devices in conduction system (CSP), biventricular (BVP), right ventricular outflow tract (RVOT), or right ventricular apex (RVA) pacing sites. The study included 102 patients: 40 with CSP (20 left bundle pacing and 20 His bundle pacing), 21 with BVP, and 20 and 21 with RVOT and RVA pacing, respectively. The percentage of positive screenings was significantly higher for CSP (97.5%) than for the other patient groups (BVP 71.4%, RVOT 70%, and RVA 19%). In multivariate analysis, positive screening was associated with a narrower QRS (OR 0.95 [0.92–0.98] P = 0.001) and higher R/T ratio in precordial leads (1.76 [1.18–2.61]).ConclusionA higher S-ICD eligibility rate of cardiac pacing device carriers was obtained in CSP than in conventional pacing (RVA or RVOT) or BVP. The presence of narrower paced QRS width and paced corrected QT interval and of higher R/T ratio in precordial and limb leads are electrocardiographic predictors of a positive response to screening.Keywords: Conduction system pacing, Screening, Subcutaneous defibrillator, Left bundle pacing, His bundle pacing What’s new? Subcutaneous implantable cardioverter-defibrillator (S-ICD) avoids intravascular access decreasing drastically the potential risk of cardiac infection. Little is known about the effect of different sites of cardiac pacing in the screening test among S-ICD carriers. Subcutaneous implantable cardioverter-defibrillator (S-ICD) avoids intravascular access decreasing drastically the potential risk of cardiac infection. Little is known about the effect of different sites of cardiac pacing in the screening test among S-ICD carriers. Conduction system pacing obtains the higher rates of positive screening compared to biventricular, outflow tract, and right ventricular apex pacing. Conduction system pacing obtains the higher rates of positive screening compared to biventricular, outflow tract, and right ventricular apex pacing. Paced QRS width, paced corrected QT interval, R/T ratio in precordial leads, and R/T ratio in limb leads revealed as a electrocardiographic predictors of positive screening. Paced QRS width, paced corrected QT interval, R/T ratio in precordial leads, and R/T ratio in limb leads revealed as a electrocardiographic predictors of positive screening. Introduction The subcutaneous implantable cardioverter-defibrillator (S-ICD) has demonstrated its efficacy in treating ventricular arrhythmias while carrying a lower risk of complications related to electrode and vascular access than conventional transvenous defibrillators.1 Before S-ICD implantation, surface electrocardiogram (ECG) screening is essential to ensure proper signal sensing and avoid any issues with T-wave oversensing. Moreover, SMART Pass™ algorithm activation should be mandatory in order to avoid inappropriate therapy.2 Cardiac pacing can alter QRS voltage and repolarization, potentially leading to changes in sensing, unfavourable screening outcomes, and even inappropriate shocks.3–5 Although S-ICD is typically reserved for patients without cardiac pacing indications, it is important to note that these indications may develop during the course of heart disease. Gasperetti et al.6 report that 2.7% of more than 1500 S-ICD carriers in their study required conversion to a transvenous device for this reason. This situation poses a challenge to the electrophysiologist, and no consensus has been achieved on its management. One option may involve extracting the S-ICD and implanting a transvenous defibrillator, although this procedure is relatively aggressive and complex compared to maintaining the S-ICD with a pacemaker implant approach. While the compatibility of cardiac pacing with S-ICD has been partially investigated in His bundle pacing (HBP),7 there has been no comparison of S-ICD screening results between different cardiac pacing sites, not even in left bundle pacing (LBP), despite its increased recommendation.8 Therefore, the objective of this study is to compare S-ICD screening results in different cardiac pacing sites and to assess the electrocardiographic predictors of successful screening outcomes. Methods This observational study enrolled carriers of cardiac pacing devices implanted between 2019 and 2021. All patients provided informed consent to participate in the study, which was approved by the hospital ethics committee. Patients were categorized into five groups based on their pacing site: right ventricular apex (RVA), right ventricular outflow tract (RVOT), biventricular pacing (BVP: coronary sinus), and conduction system pacing (HBP and LBP). Additionally, a control group of healthy volunteers with no pacing devices underwent screening. The S-ICD screening was conducted using the model 2889 EMBLEM S-ICD Automated Screening Tool (AST) from Boston Scientific (Natick, MA, USA), following the manufacturer’s instructions.9 The process was repeated for right and left parasternal views both in supine position and standing. Pure capture by the pacing electrode was tested to avoid fusion or capture complexes, increasing the pacing rate and/or reducing the atrioventricular (AV) interval in both bipolar and unipolar pacing configurations; 12-lead ECG was performed at baseline (in patients with their own rhythm) and under pacing. The pacing electrode site was determined based on chest X-ray and surface ECG results. The researcher conducting the screening was blinded to the patients’ surface ECG results. Patients were considered eligible for S-ICD implantation when at least one positive vector was present in the left or right parasternal view both in standing and in supine position. Statistical analysis Categorical data were expressed as percentages and absolute numbers and analysed with the χ2 test, while continuous data were expressed as medians and 25th and 75th percentiles and analysed using the Mann–Whitney or Kruskal–Wallis test. P < 0.05 was considered significant. Due to the small sample size of the groups (<30), non-parametric tests were used. Multivariate analysis was performed with stepwise logistic regression, entering variables associated with positive screening in bivariate analysis with P < 0.20 and deleting variables with P > 0.05. We developed a first model that did not consider the pacing sites and a second that included them. SPSS version 22 (IBM SPSS Armonk NY) was used for data analyses. Results The study included 102 patients with intracardiac devices: 40 in the conduction system pacing (CSP) groups (20 in LBP and 20 in HBP), 21 in BVP, 20 in RVOT, and 21 in RVA. The control group comprised 11 healthy volunteers with no heart disease, normal ECG, and no implanted devices. Table 1 shows the patients’ characteristics based on screening outcome. The screening was positive for 72 (70.5%) of the carriers and all of the controls. No significant differences were observed between unipolar and bipolar pacing in any group. In comparison to the CSP and BVP groups, the RVA and RVOT groups had higher mean age, left ventricular ejection fraction (LVEF), and NYHA functional class, although they had a lower prevalence of structural heart disease. The RVOT group had the highest prevalence of bundle block. At baseline, the BVP group had the widest QRS width and QT interval, while the CSP group had the narrowest QRS and the highest R/T ratio in both precordial and limb leads. Table 1Population characteristics based on screening outcomeResults variablesPositive screening n = 72 (%)Negative screening n = 30 (%) P Age (years)71 [59–79]77 [71–85]0.004Male41 (56.9)18 (60)0.836AHT46 (63.9)21 (70)0.554Diabetes mellitus38.9 (28)11 (36.7)0.833Atrial fibrillation23 (31.9)12 (40)0.435Type of pacing CSP39 (54.2)1 (3.3)0.000 Biventricular pacing15 (20.8)6 (20) Right ventricular outflow tract14 (19.4)6 (20) Right ventricular apex4 (5.6)17 (56.7)Heart disease0.422 No structural heart disease29 (40.3)15 (50) Ischaemic heart disease11 (15.3)4 (13.3) Dilated cardiomyopathy8 (11.1)4 (13.3) Hypertrophic cardiomyopathy2 (2.8)2 (6.7) Other22 (30.6)5 (16.7)LVEF at implantation0.248 Normal (>50%)40 (55.6)20 (66.7) Slightly depressed (40–50%)7 (9.7)2 (6.7) Moderately depressed (30–40%)10 (13.9)5 (16.7) Severely depressed (<30%)15 (20.8)3 (10)Conduction disorder in baseline ECG0.513 None23 (31.9)6 (20) LBBB18 (25)8 (26.7) RBBB13 (18.1)7 (23.3) LAFB8 (11.1)4 (13.3) NCD2 (2.8)0 (0) No escape rhythm8 (11.1)5 (16.7)AHT, arterial hypertension; CSP, conduction system pacing; LVEF, left ventricular ejection fraction; LBBB, left bundle branch block; RBBB, right bundle branch block; LAFB, left anterior fascicular block; NCD, non-specific conduction delay. Population characteristics based on screening outcome AHT, arterial hypertension; CSP, conduction system pacing; LVEF, left ventricular ejection fraction; LBBB, left bundle branch block; RBBB, right bundle branch block; LAFB, left anterior fascicular block; NCD, non-specific conduction delay. Characteristics by screening result The group with negative screening had a wider paced QRS (135 [120–160] vs. 120 [106–120], P = 0.001) and higher paced QTc (487 [455–518] vs. 450 [421–486], P = 0.002) but lower R/T in precordial (1.92 [1.46–2.8] vs. 3.5 [2.50–5.65], P = 0.01) and limb leads (2.50 [1.94–3.83] vs. 4.00 [3.00–6.63], P = 0.016) (Figure 1). (A) Electrocardiographic predictors related to positive screening. (B) Multivariate logistic regression analysis with ‘positive screening’ as dependent variable. (C) Multivariate logistic regression analysis with ‘positive screening’ as dependent variable including ‘pacing site’ variable. **RV apex as reference value. OR, odds ratio; CSP, conduction system pacing; BVP, biventricular pacing; RVOT, right ventricular outflow tract; pQTc, paced corrected QT interval; R/Tp, T and R wave ratio in precordial leads; R/TL, T and R wave ratio in limb leads. Screening results by pacing site The percentage of patients with positive screening was similar between the HBP and LBP groups (95% vs. 100%, P = 0.3) and was significantly higher in the combined CSP groups than in the BVP (71.4%), RVOT (70%), or RVA (19%) groups. In the multivariate model without pacing site (Figure 1B), positive screening was associated with narrower QRS (OR 0.95 [0.92–0.98], P = 0.001) and higher R/T ratio in precordial leads (1.76 [1.18–2.61]). In the multivariable model that included pacing sites (Figure 1C), the odds ratio (OR) of a positive screening (taking RVA as reference) was 112.6 (11.2–1129.9) for CSP, significantly higher (P = 0.001) than the ORs of 13.3 (1.4–123.1) for RVOT and 9.5 (1.001–90.1) for BVP (Figure 1). Conclusions A higher S-ICD eligibility rate of cardiac pacing device carriers was obtained in CSP than in conventional pacing (RVA or RVOT) or BVP. The presence of narrower paced QRS width and paced corrected QT interval and of higher R/T ratio in precordial and limb leads are electrocardiographic predictors of a positive response to screening. Conduction system pacing should be the preferred pacing modality in S-ICD carriers. Limitation The automated S-ICD screening has not been validated for paced rhythms, particularly when alternating between paced and native rhythms (off-label use). These results should be confirmed in prospective studies with a larger sample size. Contributor Information Manuel Molina-Lerma, Arrhythmia Unit, Hospital Universitario Virgen de las Nieves, Avenida de las Fuerzas Armadas, 18014 Granada, Spain; Biohealth Research Institute ibs. GRANADA, Av. de Madrid, 15, 18012 Granada, Spain. Eva Cabrera-Borrego, Arrhythmia Unit, Hospital Universitario Virgen de las Nieves, Avenida de las Fuerzas Armadas, 18014 Granada, Spain; Biohealth Research Institute ibs. GRANADA, Av. de Madrid, 15, 18012 Granada, Spain. Ricardo Rivera-Lopez, Arrhythmia Unit, Hospital Universitario Virgen de las Nieves, Avenida de las Fuerzas Armadas, 18014 Granada, Spain; Biohealth Research Institute ibs. GRANADA, Av. de Madrid, 15, 18012 Granada, Spain. Pablo Sánchez-Millán, Arrhythmia Unit, Hospital Universitario Virgen de las Nieves, Avenida de las Fuerzas Armadas, 18014 Granada, Spain; Biohealth Research Institute ibs. GRANADA, Av. de Madrid, 15, 18012 Granada, Spain. Jesús Peña Mellado, Arrhythmia Unit, Hospital Universitario Virgen de las Nieves, Avenida de las Fuerzas Armadas, 18014 Granada, Spain; Biohealth Research Institute ibs. GRANADA, Av. de Madrid, 15, 18012 Granada, Spain. Antonio Arriaga Jiménez, Arrhythmia Unit, Hospital Universitario Virgen de las Nieves, Avenida de las Fuerzas Armadas, 18014 Granada, Spain; Biohealth Research Institute ibs. GRANADA, Av. de Madrid, 15, 18012 Granada, Spain. Miguel Álvarez, Arrhythmia Unit, Hospital Universitario Virgen de las Nieves, Avenida de las Fuerzas Armadas, 18014 Granada, Spain; Biohealth Research Institute ibs. GRANADA, Av. de Madrid, 15, 18012 Granada, Spain. Data availability Database and all the information files of the current study are available from the corresponding author (M.M.-L., manuel.molina.lerma@gmail.com) on reasonable request to bona fide researchers. References Associated Data Data Availability Statement Database and all the information files of the current study are available from the corresponding author (M.M.-L., manuel.molina.lerma@gmail.com) on reasonable request to bona fide researchers.